Myovant Sciences Ltd. (MYOV) financial statements (2022 and earlier)

Company profile

Business Address SUITE 1, 3RD FLOOR
LONDON, SW1Y 4LB
State of Incorp. CA
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
TTM
3/31/2021
3/31/2020
3/31/2019
3/31/2018
3/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:52868580156109181
Cash and cash equivalents45867477156109181
Short-term investments70103   
Other undisclosed cash, cash equivalents, and short-term investments0(0)    
Restricted cash and investments   1  
Receivables194 110
Inventory, net of allowances, customer advances and progress billings73    
Inventory73    
Other undisclosed current assets21148953
Total current assets:57570588167115184
Noncurrent Assets
Operating lease, right-of-use asset81011
Property, plant and equipment332211
Other noncurrent assets187443 
Other undisclosed noncurrent assets     0
Total noncurrent assets:302018641
TOTAL ASSETS:604725106173119185
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:404544113515
Accounts payable121815 53
Accrued liabilities6629543012
Employee-related liabilities2221    
Interest and dividends payable   10 
Other undisclosed accounts payable and accrued liabilities   (44)  
Deferred revenue101 40
Debt  26  
Deferred compensation liability322    
Due to related parties01 023
Other undisclosed current liabilities125215055  
Total current liabilities:26928186723718
Noncurrent Liabilities
Long-term debt and lease obligation891193  
Long-term debt, excluding current maturities   93  
Operating lease, liability8911
Liabilities, other than long-term debt760759117100
Deferred revenue and credits00
Deferred revenue401397 
Deferred rent credit   1
Due to related parties359359114   
Other liabilities034   
Derivative instruments and hedges, liabilities     0
Other undisclosed noncurrent liabilities 29 244 
Total noncurrent liabilities:76879812897440
Total liabilities:1,0371,0792141698119
Stockholders' equity
Stockholders' equity attributable to parent(432)(354)(108)438167
Common stock000000
Common stock, share subscribed but unissued, subscriptions receivable     (0)
Additional paid in capital778709684506266252
Accumulated other comprehensive income (loss)(17)(17)(2)100
Accumulated deficit(1,193)(1,046)(791)(502)(228)(85)
Total stockholders' equity:(432)(354)(108)438167
TOTAL LIABILITIES AND EQUITY:604725106173119185

Income statement (P&L) ($ in millions)

12/31/2021
TTM
3/31/2021
3/31/2020
3/31/2019
3/31/2018
3/31/2017
Revenues23359    
Gross profit:17359    
Operating expenses(382)(318)(275)(265)(141)(56)
Other undisclosed operating income (loss)36(2) (8)(2)(28)
Operating loss:(173)(261)(275)(273)(143)(84)
Nonoperating income (expense)17164 (0)0
Investment income, nonoperating003   
Foreign currency transaction gain (loss), before tax 16  (0)0
Other nonoperating income  2   
Interest and debt expense(16)(10)(18)(9)(2) 
Loss from continuing operations before equity method investments, income taxes:(172)(255)(288)(282)(145)(83)
Other undisclosed income (loss) from continuing operations before income taxes   92(0)
Loss from continuing operations before income taxes:(172)(255)(288)(273)(143)(84)
Income tax expense (benefit)(1)(0)(1)(0)(0)0
Net loss:(173)(255)(289)(274)(143)(83)
Other undisclosed net loss attributable to parent(5)     
Net loss available to common stockholders, diluted:(178)(255)(289)(274)(143)(83)

Comprehensive Income ($ in millions)

12/31/2021
TTM
3/31/2021
3/31/2020
3/31/2019
3/31/2018
3/31/2017
Net loss:(173)(255)(289)(274)(143)(83)
Comprehensive loss:(173)(255)(289)(274)(143)(83)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(19)(16)(2)0(0)0
Comprehensive loss, net of tax, attributable to parent:(192)(271)(291)(273)(143)(83)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: